Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study

Yuelu Guo, Lixia Ma, Fan Yang, Zhonghua Fu, Danyang Li, Rui Liu, Miaomiao Cao, Bian Wei, Yimeng Dou, Biping Deng, Shilin Gan, Alex H. Chang, Xiaoyan Ke, Kai HuFrontiers in Immunology 2026 · DOI

This retrospective study, published in Frontiers in Immunology, evaluates the use of BCMA-targeted CAR-T cell therapy in patients with refractory and relapsed plasma cell leukemia (R/R PCL). The researchers found that while CAR-T therapy induces high initial response rates (75%), long-term survival likely requires consolidation with an allogeneic hematopoietic stem cell transplant (allo-HSCT).

TL;DR

BCMA CAR-T therapy provides a powerful short-term "rescue" for patients with highly aggressive, triple-refractory plasma cell leukemia, achieving a 75% response rate. However, the study suggests that CAR-T alone is rarely curative for this population; consolidating the response with an allogeneic stem cell transplant appears to be the most viable path toward long-term survival.

What Problem Does This Paper Address?

Plasma cell leukemia (PCL) is a rare and incredibly aggressive form of blood cancer. Unlike standard multiple myeloma, PCL is characterized by high levels of malignant plasma cells circulating in the peripheral blood. The prognosis is historically dismal, especially for "triple-class refractory" patients—those whose cancer has already outsmarted proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies.

While Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of multiple myeloma, its efficacy in the even more aggressive PCL landscape is less understood. Specifically, clinicians face a "what next?" dilemma: once a patient achieves remission via CAR-T, how do we prevent the almost inevitable relapse? This paper investigates whether following CAR-T with a stem cell transplant (allo-HSCT) improves outcomes.

Methods

The researchers conducted a retrospective cohort study of 12 patients treated at Beijing GoBroad Hospital between 2021 and 2025.

  • The Intervention: Patients received second-generation CAR-T cells targeting the B-cell maturation antigen (BCMA).
  • Stratification: Patients were divided into two groups:
  • Group 1 (Consolidation): Received an allo-HSCT within three months of CAR-T infusion.
  • Group 2 (Non-consolidation): Did not receive a transplant (due to disease progression, infections, or patient choice).
  • Bridging Therapy: Because PCL moves fast, many patients received "bridging" chemotherapy to keep the disease in check while the CAR-T cells were being manufactured in the lab.

Datasets

As a clinical retrospective study, the "dataset" consists of the clinical records, cytogenetic profiles, and survival outcomes of the 12-patient cohort.

  • High-Risk Features: 10 out of 12 patients had high-risk cytogenetic abnormalities, such as TP53 mutations or del(17p), which are notorious for drug resistance.
  • Baseline: All patients were triple-class refractory, representing the most difficult-to-treat segment of the PCL population.

Key Insights and Ideas

  • The "Sanctuary Site" Challenge: One patient experienced a relapse in the Central Nervous System (CNS). This highlights a known limitation of CAR-T: while the cells circulate well in the blood and marrow, they may struggle to penetrate "sanctuary sites" like the brain, allowing the leukemia to hide and eventually return.
  • Manageable Toxicity: Despite the aggressive nature of the disease, the safety profile was surprisingly favorable. While severe blood count drops (cytopenia) were universal, cytokine release syndrome (CRS) was mostly mild (Grade 1–2), and notably, no patients experienced neurotoxicity (ICANS).
  • CAR-T as a Bridge, Not a Destination: The study suggests that for PCL, BCMA CAR-T functions best as a "debulking" tool—clearing out the majority of the cancer to create a window of opportunity for a curative transplant.

Key Results

  • Overall Response Rate (ORR): 75% (9/12 patients responded). This included one complete response (CR), four very good partial responses (VGPR), and four partial responses (PR).
  • Survival:
    • Median Progression-Free Survival (PFS): 8.9 months.
  • Median Overall Survival (OS): 15.5 months.
  • The Transplant Advantage: Patients who underwent consolidation therapy (allo-HSCT) showed a trend toward better survival. Two of the four patients in the transplant group achieved long-term survival with stringent complete response, whereas all patients in the non-transplant group eventually died.

Limitations and Future Work

The primary limitation is the small sample size (n=12), which is common in studies of rare diseases like PCL but prevents definitive statistical conclusions. Additionally, as a retrospective study, there is inherent selection bias; patients who were healthy enough to make it to a transplant naturally might have had better outcomes regardless of the intervention.

The authors conclude that while BCMA CAR-T is a potent weapon for inducing remission in R/R PCL, large-scale prospective trials are needed to confirm if the CAR-T-to-allo-HSCT sequence should become the new standard of care. Future research should also explore "cocktail" CAR-T therapies (targeting multiple antigens like BCMA and CD19) to prevent the cancer from escaping via antigen loss.

Summary updated

Abstract

BCMA-CAR-T therapy confers short-term remission and survival benefits in relapsed/refractory plasma cell leukemia (R/R PCL). However, the definitive value of allogeneic hematopoietic stem cell transplantation (allo-HSCT) awaits validation in large-sample prospective studies.
BibTeX
@inproceedings{guo2026efficacy,
  author = {Yuelu Guo and Lixia Ma and Fan Yang and Zhonghua Fu and Danyang Li and Rui Liu and Miaomiao Cao and Bian Wei and Yimeng Dou and Biping Deng and Shilin Gan and Alex H. Chang and Xiaoyan Ke and Kai Hu},
  title = {{Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study}},
  booktitle = {Frontiers in Immunology},
  year = {2026},
  doi = {10.3389/fimmu.2026.1756209},
}
Figure